Starting off-label treatment with tocilizumab after the first disease attack in neuromyelitis optica spectrum disorder (NMOSD) is more effective at reducing disability than switching to tocilizumab after other therapies fail to control the disease, a study shows. Still, the risk of relapse over three years remained the same regardless…
Tocilizumab, an anti-inflammatory medication used off-label for neuromyelitis optica spectrum disorder (NMOSD), can help prevent relapses (flare-ups) and ease disability while being generally safe, according to a meta-analysis. The study, “Tocilizumab treatment in neuromyelitis optica spectrum disorders: Updated meta-analysis of efficacy and safety,” was published in the journal…
Enspryng (satralizumab) and tocilizumab — two interleukin-6 (IL-6) receptor inhibitors that prevent inflammation — are generally safe and effective for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a recent meta-analysis reported. Researchers determined these results by analyzing safety and efficacy outcomes across…
Get regular updates to your inbox.